and followed with two other licensing deals involving a pair of gene therapies for GM1 and GM2 gangliosidosis – AXO-AAV-GM1 and AXO-AAV-GM2 – from the University of Massachusetts. It also ...

Gain Therapeutics, Inc.’s GANX share price has surged by 13.74%, which has investors questioning if this is right time to sell.

At this year's symposium, the latest advances in research of the rare diseases were shared by many presenters, including GC Biopharma's poster presentations on the non-clinical study results of ...